Salvage HDR brachytherapy had low severe toxicity but limited five-year biochemical control

Five-year PSA progression-free survival was 24.8% after two-fraction salvage HDR brachytherapy without androgen deprivation, despite low severe toxicity.

KEY POINTS

  • This prospective phase II study treated 30 patients with biopsy-confirmed, MRI-visible local prostate cancer recurrence after prior external-beam radiotherapy. Median follow-up after salvage HDR brachytherapy was 72 months, providing unusually mature prospective follow-up for this setting.
  • MRI-assisted ultrasound-guided treatment delivered 21 Gy to the whole prostate and 27 Gy to the MRI-defined recurrent intraprostatic target, divided across two implants separated by 1–2 weeks. No concurrent or adjuvant androgen-deprivation therapy was given.
  • PSA progression-free survival was 73.0% at three years but only 24.8% at five years, with median biochemical recurrence-free survival of 44.1 months. Freedom from starting androgen deprivation remained 93.0% at three years and 69.6% at five years.
  • Recurrence was frequently local despite the intraprostatic boost. 23/30 patients (77%) eventually experienced PSA relapse, and 18/23 relapsing patients (78%) had recurrent or persistent disease at the treated target documented by MRI, PSMA PET or targeted biopsy. Among 26 patients with post-treatment MRI, 9 (35%) already had persistent disease.
  • Severe toxicity was uncommon: there was one grade 3–5 event among 30 patients (3.3%), a late grade 3 genitourinary toxicity, and no grade 3–5 gastrointestinal toxicity. Temporary urinary catheterization was required in 4 patients (13%).
  • Grade 2 urinary symptoms were much more frequent than severe events: the authors report 86% acute and 70% late grade 2 urinary retention, partly reflecting routine alpha-blocker use. Patient-reported urinary and bowel quality-of-life domains showed an acute decline followed by recovery toward baseline during long-term follow-up.
  • The efficacy estimate should be interpreted in the context of evolving staging: only 7/30 patients (23.3%) underwent PSMA PET staging and 77% entered before its routine introduction, so some patients may have harbored occult metastatic disease. The small cohort also cannot reliably quantify rare severe late events, and MRI-to-ultrasound fusion techniques evolved during accrual.

CLINICAL TAKEAWAY

Whole-gland salvage HDR brachytherapy with an MRI-defined boost can defer systemic therapy for selected men and produced remarkably little severe late toxicity. However, five-year biochemical control was poor with this two-fraction, no-ADT regimen, and frequent recurrence at the treated target argues for further work on dose, fractionation, patient selection and systemic therapy integration.

SOURCE

Advances in Radiation Oncology

Browse more research Suggest a correction